Aethlon Medical (NASDAQ:AEMD) Stock Crosses Above 200 Day Moving Average of $3.50

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.50 and traded as high as $3.56. Aethlon Medical shares last traded at $3.51, with a volume of 655,705 shares.

A number of research firms recently weighed in on AEMD. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of Aethlon Medical in a research report on Friday, June 25th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Aethlon Medical in a research report on Tuesday, August 10th.

The business’s 50 day simple moving average is $3.82 and its 200 day simple moving average is $3.50.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Sunday, August 8th. The medical equipment provider reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts forecast that Aethlon Medical, Inc. will post -0.62 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of AEMD. Citadel Advisors LLC bought a new position in shares of Aethlon Medical in the first quarter valued at approximately $29,000. Millennium Management LLC bought a new position in shares of Aethlon Medical in the first quarter valued at approximately $30,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical in the first quarter valued at approximately $40,000. Northern Trust Corp raised its stake in shares of Aethlon Medical by 77.1% in the first quarter. Northern Trust Corp now owns 21,490 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 9,356 shares during the last quarter. Finally, State Street Corp bought a new position in shares of Aethlon Medical in the second quarter valued at approximately $96,000. Institutional investors own 5.53% of the company’s stock.

Aethlon Medical Company Profile (NASDAQ:AEMD)

Aethlon Medical, Inc is a medical technology company, which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.

Further Reading: What is a trade deficit?

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.